68  Rhee E, Feng H-P, Xuan F et al. Absence of a significant pharmacokinetic interaction BMS-354825 order between the hepatitis C virus protease inhibitor boceprevir and HIV-1 NNRTI rilpivirine. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA. March 2013 [Abstract 537]. 69  NICE technology appraisal guidance TA253. Boceprevir for the treatment of genotype 1 chronic hepatitis C: April 2012. Available at: http://guidance.nice.org.uk/TA253 (accessed May 2013). 70  NICE technology appraisal guidance TA252. Telaprevir for the treatment of genotype 1 chronic hepatitis C: April 2012. Available at: http://guidance.nice.org.uk/TA252 (accessed May 2013).

71  Sulkowski M, Sherman K, Dieterich D et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; epub ahead of print doi: 10.7326/0003-4819-159-2-201307160-00654. 72  selleck inhibitor Sulkowski M, Pol S, Mallolas J et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597–605. 73  Ahmed A, Pepper S, Page E, Anderson M, Nelson M. Clinical Experience of Boceprevir for the Treatment of Chronic Hepatitis C in HIV Coinfection. 3rd International Conference on Viral Hepatitis. New York,

NY. March 2013 [Abstract 24]. 74  Martel-Laferrière V, Brinkley S, Bichoupan K et al. On-Treatment Responses to Telaprevir-Based Hepatitis C Treatment Are Similar in HIV/HCV Coinfected and HCV-Monoinfected Patients. 3rd Glutamate dehydrogenase International Conference on Viral Hepatitis. New York, NY. March 2013 [Abstract 31]. 75  Cotte L, Braun J, Lascoux-Combe C et al. High Early Virological Response with Telaprevir-Pegylated-Interferon-Ribavirin in Treatment-experienced Hepatitis C Virus Genotype 1/HIV Co-infected Patients: ANRS HC26 TelapreVIH Study. 20th Conference

on Retroviruses and Opportunistic Infection. Atlanta, GA. March 2013 [Abstract 36]. 76  Poizot-Martin I, Bellissant E, Piroth L et al. ANRS-HC27 BocepreVIH Interim Analysis: High Early Virologic Response with Boceprevir + Pegylated Interferon + Ribavirin in Hepatitis C Virus/HIV Co-infected Patients with Previous Failure to Pegylated Interferon + Ribavirin. 20th Conference on Retroviruses and Opportunistic Infection. Atlanta, GA. March 2013 [Abstract 37]. 77  Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis 2013: 207(Suppl 1): 26–32. 78  Jacobson I, Dore G, Foster G et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam, The Netherlands. April 2013 [Abstract 1425]. 79  Ferenci P, Asselah T, Foster GR et al.